HEE Corporation Announces Their Proprietary Product, HPB 84 will be Featured on HEALTH JOURNAL TELEVISION and CNBC Tuesday October 26, 3:23 pm ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Oct. 26, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce their proprietary product, HPB-84, will be featured on HEALTH JOURNAL TELEVISION and CNBC beginning on October 29, 2004. Health Journal Television is hosted by Alexander Haig and directed by Emmy Award winner Alan Levy. The shows format is a news magazine featuring leading corporate executives and industry experts, as well as informative field reports. Health Journal Television is independently produced by Multi-Media Productions USA, Inc., and is distributed worldwide on CNBC, Bravo and Tech TV, Health and Science Television Network (HSTN), Long Term Care Network (LTCN), Asia Television and multiple medical universities throughout the United Sates. For information as to when the show will be airing, readers are directed to use the following link, www.healthjournaltv.com, or to consult the following link, www.hee-corp.com/hji.doc for a complete listing of show times and stations.
ABOUT HEE CORPORATION
The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not yet aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide.
NOTE: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations. ------------------------------------------------------------------------ Contact:
posted
yep i'll be sure to watch this one a couple of times. i'mma hopin' this will change the way this thing has been trading lately. X'n fingers.....
Posts: 829 | From: people's republic of cambridge | Registered: Jun 2004
| IP: Logged |
posted
HEE Corporation Announces an Additional Clinical Trial Wednesday October 27, 4:21 pm ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Oct. 27, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce their proprietary product, HPB-84 will be the subject of an additional clinical trial. Management met with a company last week to discuss basic elements of the study with principals of the company. The research company currently has six (6) other clinical trials underway on drugs developed for diabetic patients. Investigative protocols are currently in development and, once approval is obtained from the IRB (Investigative Review Board), the trial will get underway. We anticipate having the results from this trial is approximately 4-6 months. HEE Corporation updates test results achieved by three (3) patients
HEE Corporation is pleased to publish the updated test results being achieved by three (3) patients. Two of the patients are on the maintenance program and one is undergoing active treatment.
Ron Brooks has been averaging a blood glucose level of 93; Stan Casad has been averaging a blood glucose level of 110. The new patient started treatment on October 16th with a blood glucose level of 154 and dropped to 104 earlier this week.
These results certainly demonstrate the dramatic improvements these patients are achieving by using HEE Proprietary Blend 84.
ABOUT HEE CORPORATION
The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not yet aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide.
NOTE: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations.
-------------------------------------------------------------------------------- Contact: The HEE Corporation 620-663-3333 www.hee-corp.com
posted
i hope it will turn around too. picked up some hccfp as well - .004 this morning. anyone managed to watch the tv show?
Posts: 734 | Registered: Sep 2004
| IP: Logged |
If the HPB-84 goes to market, as I expect it will, with the results it is showing in patients lately this stock could very easily hit $20-$30.
hope it will be as what you said. i am willing taking a risk on this one. my family has history of diabety. my dilema is when ever my holdings release good news, pps goes down.
Dr.No's opinions (AND THESE ARE ONLY OPINIONS): 95% of pink sheet stocks are duds. I think that the HCCF has good potential to be in the 5% of successful pink sheet companies. The company was pleased by the treatment's test results during the third quarter. A new group of test patients has been selected and testing began on October 11, 2004. The stock did not show any sustainable price-per-share gain after the third quarter's test results were announced. Patience is the key on this one. I have been watching this since August and I am not taking action at this time. The stock fell through it's last support level of .11 and appears to show no indication of a reversal at this time. This could easily drop to .05 to .03 and may possibly trade under a penny in the forth quarter or ealry 2005. This stock is definately one to put on the 'watch list'. These are only opinions. As with any investment, do your own research and don't make decisions based solely on statements from message boards.
-HCCF is one of my picks for 2005 and I will be updating this thread as I see fit.-
posted
FOR YOUR INFO...HERE IS FROM OTHER BOARDS CONCERNING CALLS TO COMPANY::
IR doesn't know why the shareprice is so low.
In fact, the company continues to make progress & considers the second trial (announced last night) to be a POSITIVE development. They are just as frustrated with the share manipulation as regular shareholders and will be releasing updates/info as soon as it becomes available.
Call them to find out for yourself ---------------------------------------------------------------
I spoke with them today also. Said same thing to me regarding not knowing what was going on with price as of late. Surprising to them considering everything is going so great at the company, brought in 2 advisors for business plans, made deal with university, which is a really BIG deal, wish they could say more about it. Does anyone know the outstanding shares? They told me 72,000,000, does that sound right, also that is after issuing the dividend shares. Is it also right that when the other shares were issued, the price was around 10 cents? My guess, once whoever is done selling there preferred shares, price will rebound. They said there was no restrictions put on shares, so that is why my conclusion. They seem to need some MAJOR help in the IR department though!
quote:Originally posted by Bigrod40: FOR YOUR INFO...HERE IS FROM OTHER BOARDS CONCERNING CALLS TO COMPANY::
IR doesn't know why the shareprice is so low.
In fact, the company continues to make progress & considers the second trial (announced last night) to be a POSITIVE development. They are just as frustrated with the share manipulation as regular shareholders and will be releasing updates/info as soon as it becomes available.
Call them to find out for yourself
i also had the same answers from the IR last sept. ir said mm manipulation - and could be competition reason as well since the industry is multi-billion dollars. i still remember that i traded this stock in jul for 95 cents.
this pr didnt appear in yahoo finance. thank for posting.
this one came out yesterday
HEE Corporation Announces Double Blinded Placebo Controlled Clinical Studies Will Commence Soon Tuesday November 2, 5:00 pm ET HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 2, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce their proprietary product; HPB-84 will be the subject of a double blinded placebo controlled clinical trial at a major university. Management met with the University last week to discuss basic elements of the study with key personnel of the university. As a requirement of the study, HEE Corporation has agreed to refrain from mentioning the university and lead investigators. However, the lead investigator is very well known in health care and is highly regarded by peers as well as the American Diabetes Association. Double blinded placebo controlled clinical studies are the "gold standard" for any new medical procedure, drug, or treatment protocol. HEE Corporation is very excited to have been able to achieve this milestone. ABOUT HEE CORPORATION The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not even aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide.
this one pop out from search: Posted on Sat, Oct. 23, 2004
A deal to sell the building that once housed Halstead Hospital and the Hertzler Clinic to a Hutchinson company is "essentially dead," said an executive with the building's owner.
HEE Corp., a publicly-traded Hutchinson company that markets a homeopathic treatment for type II diabetes, announced in early September that it had bought the building. Halstead is a small Harvey County town 10 miles west of Newton.
The building's owner is Valley Hope Association, a large nonprofit drug treatment organization based in Norton.
The sale ran into problems two weeks ago, Valley Hope president Dennis Gilhousen said. After a flurry of negotiations this week, he said, the deal appears dead.
"We're still interested in selling, and I hope the prospects are good," Gilhousen said. "I think our prospects of concluding the sale with HEE Corp. are essentially dead."
He said he is talking with two other health care related buyers, but couldn't say more because of potential legal issues stemming from the HEE Corp. negotiations.
HEE Corp. chairman Ron Brooks wouldn't comment Friday, but he did release a statement earlier in the week.
In the statement, Brooks said the property appraisal hadn't been completed. He also said the lenders were requiring an environmental assessment, remodeling plans, and unspecified legal and regulatory requirements.
"It was probably unrealistic of us to believe we could close such a large real estate transaction in such a short time," he said in the statement.
He said HEE Corp. was searching for other space.
Halstead Hospital closed as a hospital in September 2002, less than three months after filing for Chapter 11 bankruptcy protection.
Its last chief executive, Barry Nelson, was later charged with misapplying employee health care premiums and embezzling money from employee pensions.
Since buying the hospital in February 2003, Valley Hope has been using part of it for a 60-bed substance abuse treatment clinic.
Twice in the last year, groups have approached Valley Hope about buying the building, but neither deal worked out.
[This message has been edited by tqn (edited November 04, 2004).]
quote:Originally posted by zippycal: How much lower can this one go ?
I had it before at .20 and got out at just under $1.
Does anyone think it will get back up there again ? I think it has a real good chance with the new tests. I bought at .047 yesterday.
chris
i got out at .95 and back in at .2. some speculated that it might become a sub-penny. oh well, too late for me to bail. hold on for a few years until all the tests done. who knows, it would become a gold mine. once it hits the bottom, i will load up more to average down. may be, we just have to wait for those marketing or service guys who got paid by shares finishing their dumping before we see green again.
[This message has been edited by tqn (edited November 05, 2004).]
HEE Corporation Announces Decision to Discontinue Effort to Acquire Halstead Hospital Monday November 8, 11:07 am ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 8, 2004--HEE Corporation (HCCF on OTC Pink Sheets) announces their decision to discontinue their efforts to acquire the Halstead Hospital. As a result of recent intensive strategic planning efforts management determined it would be inappropriate to continue to move forward with the acquisition of the Halstead Hospital. Alternative marketing strategies clearly demonstrated a less intensive use of capital offered an increased rate of return for the shareholders. Moreover, the establishment of smaller clinics in diverse geographic locations could be opened more quickly and more economically and would position the company to provide services to patients throughout a broader geographic area. Management believes it is important to be able to provide services that are accessible, convenient, and can be opened in a relatively short period of time. We believe this type of approach will increase the opportunity to generate income for our shareholders and represents a more effective use of capital.
posted
HEE Corporation Announces the Appointment of Eric Smith to the Advisory Board Thursday November 11, 5:10 pm ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 11, 2004--HEE Corporation (Pink Sheets:HCCF - News) is pleased to announce the appointment of Mr. Eric Smith to the Advisory Board. Eric Smith is currently a director at Rising Star Holdings, where he manages investments throughout the US and Asia. Mr. Smith has worked in private equity, business development, and strategy consulting for the past 7 years. He is considered an authority on the biotechnology and pharmaceutical sectors in India and China. His paper Opening Up to the World: India's Pharmaceutical Companies Prepare for 2005 (Stanford Asia Pacific Research Center, 2000) is widely regarded as one of the most definitive reports on Indian pharmaceuticals to date. Mr. Smith holds a BA from Pomona College an MA from Stanford University. ABOUT HEE CORPORATION
The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not even aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide.
For more information contact HEE Corporation at 620-663-3333 or visit our web site at www.hee-corp.com.
posted
From: T*** Sent: Wednesday, November 10, 2004 5:22 PM To: ir@hee-corp.com Subject:
Dear Investor Relation, We investors are crying out heart out for the big hit in price per share of Hee Corp. Is there any chance we can ask the company to give us any economic or financial reason for this drop. If it's the market manipulation, it's illegal and what the company is going to do about it. Many of us still have faith in the development of Hee Corp. but it's hard to see our investment dropped. Regards, T****
Date: Thu, 11 Nov 2004 10:48:17 -0600
Dear Mr. N****,
Thank you for your e-mail concerning our stock price. It is unfortunate for all of us that our stock price is at the price that it is at this time. The price doesn't at all reflect accurately the success that our company is having. We have many good things happening within our company at this time. We are now beginning the studies through the university that we mentioned in a previous press release. We are also conducting a local study. We will be releasing news on these as soon as possible.
We are doing everything possible to find out who is dumping shares and why. The company is also buying stock to try to keep up with the dumping. It has to end soon. We appreciate your continued faith in HEE Corporation. We are looking forward to the opportunity to help millions of people who are suffering from type II diabetes.
posted
HEE Corporation Announces Appointment of Jamian Lai to the Advisory Board Friday November 12, 1:01 pm ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 12, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce the appointment of Mr. Jamian Lai to the Advisory Board. Mr. Lai is the General Manager of the Vancouver Rising Stars. In addition to his role as GM of Rising Stars, Jamian Lai manages venture projects for RSH in the US and China. Previous to RSH, Mr. Lai helped found a Pan-Asia strategy consulting firm that served large corporations in Asia, including Hyundai Motors, Applied Materials, UPS and Siemens. Prior to founding Kaptiva, Jamian worked at the investment bank Morgan Stanley where he served in the Global High-Yield and Commodities groups. Mr. Lai has an MBA from Harvard University and has also studied at Beijing University.
posted
HEE Corporation Announces Signing Business Associate Agreement with Physician Research Network of Kansas Tuesday November 16, 10:29 am ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 16, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce the signing of a Business Associate Agreement with Physician Research Network of Kansas. (www.prnofkansas.com) According to a company spokesperson, this agreement is a landmark step in formalizing a developing relationship that will enable us to begin the organized intake of additional test subjects as well as prospective patients. PRN is a dedicated research network committed to managing and coordinating clinical research activities involving investigational drugs and medical devices with the highest possible quality and efficiency. They offer a collaborative, multi-specialty, research network that provides a wide variety of new clinical trial opportunities to the health care industry and allows HEE Corp to have access to a large number of health care organizations and companies.
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 19, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce the opening date for the first HEE Wellness Center. A company spokesperson stated this is an exciting step toward HEE offering HPB-84 to the general public. HEE also plans to offer preventative health services to prospective patients, employer health plans and other clients. The center will commence operation on November 30, 2004. Additional details and means of contacting the center will be the subject of future releases.
ABOUT HEE CORPORATION
The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not even aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide.
NOTE: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations.
posted
If only 1/10th of type II diabetics spent 20 dollars it would be a great success.
18.2 mil/10 = 1.82 million X 20 = 36 million.
Since it is a treatment not a cure I think dollars per patient produce a real residual income valued much higher.
This stock is so undrvalued it isn't even funny. imo I couldn't find the OS but even with a billion shares it should be potentially double or triple its current level.
Posts: 279 | From: Neodesha Ks USA | Registered: Jun 2004
| IP: Logged |
posted
I have been watching CDIK as well. Both seem really promising and I like medical technology. My investment might help someone.
Posts: 279 | From: Neodesha Ks USA | Registered: Jun 2004
| IP: Logged |
posted
Here is a few other companies he has owned or still owns...
Additional SANDY WINICK entities (as of 10/1/04 12:19 am)
1. ADATOM.COM, INC. DOMESTIC CORPORATION, OR ACTIVE 2. AQ TERRITORIAL HOLDINGS, LTD. DOMESTIC CORPORATION, OR ACTIVE 3. BROADSPOT WIRELESS, INC. CORPORATION, NV DELINQUENT 4. DISTRIBUTED DIAGNOSTICS INC. CORPORATION, NV DELINQUENT 5. EQUIART INCORPORATED DOMESTIC CORPORATION, OR ACTIVE 6. EQUITY RETIREMENT SAVINGS DISTRIBUTORS INC. CORPORATION, NV REVOKED 7. EXTREME POKER LTD. CORPORATION, NV DELINQUENT 8. FEINSTEIN REPORT, INC., THE CORPORATION, NV DELINQUENT 9. FIRST PUBLIC SECURITIES TRANSFER CORPORATION DOMESTIC CORPORATION, OR ACTIVE 10.FORM 59, INC. CORPORATION, NV DELINQUENT 11.GAMBOA PROPERTIES, INC. DOMESTIC CORPORATION, OR ACTIVE 12.OIL EXPLORATION INTERNATIONAL, INC. DOMESTIC CORPORATION, OR ACTIVE 13.OPTICAL GRAPHICS, INC. CORPORATION, NV DELINQUENT 14.PROGOLFTOURNAMENTS.COM, INC. FOREIGN CORPORATION, FL INACTIVE 15.SPRINGERVILLE NATURAL PURE MOUNTAIN WATER INC. CORPORATION, NV PERMANENTLY REVOKED 16.TAONGI REAL ESTATE AND DEVELOPMENT CORPORATION DOMESTIC CORPORATION, OR ACTIVE 17.THE CURCIO GROUP, INC. DOMESTIC CORPORATION, OR ACTIVE 18.THE INTERNATIONAL MONETARY RESERVE, INC. DOMESTIC CORPORATION, OR ACTIVE 19.TIMR, INC. DOMESTIC CORPORATION, OR ACTIVE 20.AMR GOLD RESOURCES INC. CORPORATION, NV, Default 21.CROSSSTREET DISTRIBUTION, INC. (formerly ENERGY CONCEPTS, INC.) CORPORATION, WY
PRINCIPAL INFORMATION
Name: SANDY WINICK Title: PRESIDENT Address: 6021 YONGE ST #212, TORONTO, CANADA M2M030000
posted
Here is 2 other companies he resigned from this year...
TORONTO--(BUSINESS WIRE)--Jan. 29, 2004
Future Quest, Inc. (FUQUF.PK,) announced today that the shareholders elected a new board of directors at a shareholder meeting held on January 26, 2004. The individuals elected were Tim DeHerrera and Rocky Khanna. At this time Mr. DeHerrera was also appointed President of the company. Sandy Winick, the sole Director and President, resigned effective the same date.
VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 18, 2004
Fossil Graphics Inc. (Pink Sheets:FOSSF), is pleased to provide the shareholders with the following update, effective February 09, 2004. Philip Fraser has been appointed as the new Chairman, Director and President of the Company. Frank Cameron will also be serving on the Board of Directors of Fossil Graphics. The Company accepts the resignation of Sandy Winick as director and officer of the Company.
posted
HEE Corporation Announces Appointment of Timothy W. Lawton, MD as Medical Director Friday November 19, 4:36 pm ET
HUTCHINSON, Kan.--(BUSINESS WIRE)--Nov. 19, 2004--HEE Corporation (HCCF on OTC Pink Sheets) is pleased to announce the appointment of Timothy W. Lawton, MD as Medical Director. Dr. Lawton is a graduate of the University of Iowa College of Medicine and the McCormick School of Engineering at Northwestern University with a degree in Biomedical Engineering. Dr. Lawton is Board Certified Family Physician and licensed in Kansas and Illinois. Dr. Lawton has also served as a Clinical Instructor for visiting physicians and made numerous presentations on Diabetes, Cardiovascular Disease and Obesity. Additionally, Dr. Lawton conducted research on the effects of steroid hormones on intracellular pH of renal cells; a medical problem often encountered by diabetics. A company spokesperson stated we are very fortunate to have secured the services of Dr. Lawton as he is exceptionally well qualified to meet the needs of HEE Corp. We believe this is an exciting step forward for HEE. Dr. Lawton has assisted us greatly in developing the protocols to be employed at the HEE Wellness Centers. Among other things, Dr. Lawton will be responsible for the supervision of the HEE Wellness Centers and additional research on HPB-84.
posted
These after the BELL PRs on Fridays kill me, I hate having to wait for Mondays. Anyways HCCF, in my eyes, sure looks like a winner. Thier first PR is great, I like the part about trying to line up outfits that have health benefit plans. That in itself is a Multi-billion dollar bussiness, when dealing with unionized corporations. Then you have the extremely promising neutriceutical treatment for Type II Diabetes proprietary product, HPB-84 (Once Federal Approval is given) All I can say is LOOK OUT, this price of .025 is a steal.
Posts: 1637 | Registered: Apr 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
